GSK Stock Recent News

GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner. The pharmaceuticals developer said it has received 'breakthrough therapy designation' from the US Food and Drug Administration (FDA) for the antibody-drug conjugate to treat relapsed or refractory extensive-stage small-cell lung cancer, an aggressive form of lung cancer.

British pharma multinational GSK PLC (LSE:GSK, NYSE:GSK) has persistently been undervalued against its international peer set due to merited fears over the high-profile Zantac litigation. But with recent victories in the US courts, is this discount beginning to look unfair?

British drugmaker GSK said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer.

GSK PLC (LSE:GSK, NYSE:GSK) has secured a legal victory in the ongoing Zantac (ranitidine) litigation, with the Florida State court in the US excluding the plaintiffs' expert testimony as unreliable. Thousands of lawsuits have been filed against the British drugmaker alleging that the Zantac heartburn medication's active ingredient ranitidine causes cancer.

Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platform Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areas Invoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreement Dosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMO Strengthening of Supervisory Board with appointment of innovation expert Birgit Hoffman and clinical oncologist Mehdi Shahidi, M.D. Chief Financial Officer, Pierre Kemula, to step down at the end of his term October 31, 2024; search for a replacement ongoing with transition plan in place Cash and cash equivalents position o

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV.

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury found that the product was not responsible for plaintiff Carrie Joiner's colorectal cancer. Joiner had alleged that she developed cancer from a carcinogenic contaminant called NDMA in the blockbuster pill.

GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spokesperson said.

On Thursday, Moderna Inc  MRNA lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines.